Skip to main content
PMC home page
Molecular Cancer logoLink to Molecular Cancer
. 2021 Jan 27;20:21. doi: 10.1186/s12943-021-01319-5

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Yann Cheli 1,✉, Meri K Tulic 2, Najla El Hachem 3, Nicolas Nottet 1, Arnaud Jacquel 4, Maeva Gesson 5, Thomas Strub 1, Karine Bille 1, Alexandra Picard-Gauci 6, Henri Montaudié 6, Guillaume E Beranger 1,2, Thierry Passeron 2,6, Pierre Close 3, Corine Bertolotto 1,#, Robert Ballotti 1,#
PMCID: PMC7839296  PMID: 33504341

Correction to: Mol Cancer (2021) 20:12

https://doi.org/10.1186/s12943-020-01306-2

Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

Supplementary Information

Additional file 1. (599.2KB, pdf)

Footnotes

Corine Bertolotto and Robert Ballotti contributed equally to this work.

Reference

  • 1.Cheli Y, Tulic MK, El Hachem N, et al. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer. 2021;20:12. doi: 10.1186/s12943-020-01306-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1. (599.2KB, pdf)

Articles from Molecular Cancer are provided here courtesy of BMC

RESOURCES